Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  van Luijn, Marvin M ^a,b   van de Loosdrecht, Arjan A ^a   Lampen, Margit H ^c   van Veelen, Peter A ^c   Zevenbergen, Adri ^a   Kester, Michel G D ^c   de Ru, Arnoud H ^c   Ossenkoppele, Gert J ^a   van Hall, Thorbald ^c   van Ham, S Marieke ^b  

^a University of Amsterdam   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHAIN II ASSOCIATED INVARIANT CHAIN PEPTIDE; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B40 ANTIGEN; HLA B7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2;

ALLELE; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING ASSAY; CANCER CELL CULTURE; CELL MEMBRANE; CELL SURFACE; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LEUKEMIA CELL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; INVARIANT CHAIN; LEUKEMIA; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS MUSCULUS;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE, TUMOR; CELL MEMBRANE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; LEUKEMIA; MICE; MICE, TRANSGENIC; PROTEIN BINDING;

EID: 84860380165     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034649     Document Type: Article

References (47)

1. Elliott EA, Drake JR, Amigorena S, Elsemore J, Webster P, et al. (1994) The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med 179: 681-694.
2. Romagnoli P, Germain RN, (1994) The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 180: 1107-1113.
3. Fling SP, Arp B, Pious D, (1994) HLA-DMA and-DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 368: 554-558.
4. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, et al. (1995) Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375: 802-806.
5. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S, (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci U S A 94: 6886-6891.
6. van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, et al. (2010) Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother 59: 1825-1838.
7. van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, et al. (2010) Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica 95: 485-493.
8. Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, et al. (2008) The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes. Cancer Immunol Immunother 57: 389-398.
9. Anderson MS, Miller J, (1992) Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89: 2282-2286.
10. Roche PA, Cresswell P, (1990) Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345: 615-618.
11. Koch J, Tampe R, (2006) The macromolecular peptide-loading complex in MHC class I-dependent antigen presentation. Cell Mol Life Sci 63: 653-662.
12. Bevan MJ, (2006) Cross-priming. Nat Immunol 7: 363-365.
13. Di Pucchio T, Chatterjee B, Smed-Sorensen A, Clayton S, Palazzo A, et al. (2008) Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 9: 551-557.
14. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C, (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9: 558-566.
15. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, et al. (2003) ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425: 397-402.
16. Arunachalam B, Lamb CA, Cresswell P, (1994) Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int Immunol 6: 439-451.
17. Pieters J, Bakke O, Dobberstein B, (1993) The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 106 (Pt 3): 831-846.
18. Faure-Andre G, Vargas P, Yuseff MI, Heuze M, Diaz J, et al. (2008) Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science 322: 1705-1710.
19. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J, (1993) The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 74: 257-268.
20. Zwart W, Peperzak V, de VE, Keller AM, van der HG, et al. (2010) The invariant chain transports TNF family member CD70 to MHC class II compartments in dendritic cells. J Cell Sci 123: 3817-3827.
21. Kessler JH, Mommaas B, Mutis T, Huijbers I, Vissers D, et al. (2003) Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 64: 245-255.
22. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, et al. (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 66: 1147-1154.
23. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, et al. (2004) Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 64: 1867-1874.
24. Parham P, Brodsky FM, (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3: 277-299.
25. Meiring HD, van der Heeft E, ten Hove GJ, de Jong APJM, (2002) Nanoscale LC-MS(n): technical design and applications to peptide and protein analysis. Leuk Res 25: 557-568.
26. Lundegaard C, Lund O, Nielsen M, (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24: 1397-1398.
27. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, et al. (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36: W509-W512.
28. Hiemstra HS, Duinkerken G, Benckhuijsen WE, Amons R, de Vries RR, et al. (1997) The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. Proc Natl Acad Sci U S A 94: 10313-10318.
29. Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, et al. (1996) Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol 156: 2473-2480.
30. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, et al. (2010) Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 70: 8339-8346.
31. Melnick A, Licht JD, (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215.
32. Cerundolo V, Elliott T, Elvin J, Bastin J, Townsend A, (1992) Association of the human invariant chain with H-2 Db class I molecules. Eur J Immunol 22: 2243-2248.
33. Sugita M, Brenner MB, (1995) Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments. J Biol Chem 270: 1443-1448.
34. Harris PE, Maffei A, Colovai AI, Kinne J, Tugulea S, et al. (1996) Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood 87: 5104-5112.
35. Rammensee HG, Friede T, Stevanoviic S, (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
36. Sette A, Sidney J, (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 50: 201-212.
37. Lampen MH, Verweij MC, Querido B, van der Burg SH, Wiertz EJ, et al. (2010) CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population. J Immunol 185: 6508-6517.
38. Seidel UJ, Oliveira CC, Lampen MH, van Hall T, (2012) A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol Immunother 61: 119-125.
39. van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, et al. (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12: 417-424.
40. van Luijn MM, van den Ancker W, Chamuleau ME, Zevenbergen A, Westers TM, et al. (2011) Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res 71: 2507-2517.
41. Reber AJ, Turnquist HR, Thomas HJ, Lutz CT, Solheim JC, (2002) Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics 54: 74-81.
42. Vigna JL, Smith KD, Lutz CT, (1996) Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove. J Immunol 157: 4503-4510.
43. Powis SJ, (2006) CLIP-region mediated interaction of Invariant chain with MHC class I molecules. FEBS Lett 580: 3112-3116.
44. Weenink SM, Milburn PJ, Gautam AM, (1997) A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules. Int Immunol 9: 317-325.
45. Veenstra H, Jacobs P, Dowdle EB, (1996) Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Cell Immunol 171: 68-73.
46. Moller P, Koretz K, Schlag P, Momburg F, (1991) Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int J Cancer (Suppl 6): 155-162.
47. Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, et al. (2012) A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 13: 237-245.